Pfizer Inc. Stock

One particular type of drug has become a household name in recent times, and that's a class known as GLP-1. Originally approved for type 2 diabetes, these drugs also showed strengths in weight loss

Shares of Pfizer (NYSE: PFE) have fallen 55% from their late 2021 high. That decline highlights a material change in Wall Street's view of the pharmaceutical giant. And it has pushed the dividend

Investors should always consider the long game when looking at stocks. Even if a business is not doing well right now, that doesn't mean it'll always be the case. Looking at a broader time frame can

There are many criteria for evaluating a pharmaceutical stock, but one of the easiest to start with is the drug pipeline. You can do so by looking at quarterly reports or listening to earnings

As large tech companies struggled this year, investors have had a chance to reevaluate their portfolios and identify where they may be underexposed to certain sectors.

One of those sectors may be

Although high dividend yields are attractive to income seekers, they can sometimes signal that the dividend is unsustainable and a payout cut is on the way. Is that where we are headed with Pfizer

On the second trading day of the week, Pfizer (NYSE: PFE) was a laggard on the stock exchange. An analyst reiterated his bearish view of the stock, and more than a few investors were obviously

One of the most puzzling stocks these days is Pfizer (NYSE: PFE). Although it's not generating tons of money from its COVID vaccine and pill anymore, the business is still doing well. There are

Pfizer (NYSE: PFE) investors got some very bad news when the company was forced to abandon its internally developed GLP-1 weight loss drug in April, 2025. With patent expirations on the horizon

When you think of GLP-1s and investing, the two large pharmaceutical companies benefiting most from this trend may first come to mind. First, there's Novo Nordisk, the first to bring GLP-1 weight

After years of lagging the market, has Pfizer (NYSE: PFE) finally found a spark? With unimpressive financial results and recent launches that have not generated enough sales to turn things around,

Pfizer (NYSE: PFE) stock hasn't made for a good investment over the past five years. It has declined by 25% in value over that stretch, while the S&P 500 has climbed by 68%. Investors have lost

Pfizer (NYSE: PFE) and Moderna (NASDAQ: MRNA) were both leaders in the coronavirus vaccine market. However, as sales of these products have declined significantly in recent years -- due to the

It's not hard to find healthcare stocks, including small-cap biotech companies, trading below $50 per share. However, many of these are high-risk investments that are likely to destroy investors'

Pfizer (NYSE: PFE) has had its share of ups and downs in recent years. The pharma giant scored a major win in early pandemic days as it brought its coronavirus vaccine and later a coronavirus

The wash-out from the COVID-19 pandemic has been brutal for any pharmaceutical stock. Pfizer (NYSE: PFE) has been no exception. As a vaccine maker, Pfizer has faced headwinds to growth in the last

Some indicators suggest that equity markets are currently overvalued. For instance, the S&P 500 Shiller CAPE ratio is near multi-year highs. In this environment, it pays to look for bargains, stocks